Second Line Breast Cancer Trial
The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.
Advanced Breast Cancer
DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Fulvestrant
time to tumor progression, Every 3 months
objective tumor response, Every 3 months|time to treatment failure, Every 3 months|time to death, Every 3 months
The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.